LifeVantage (LFVN) announced the completion of an international in vitro cell study that investigated the effects of its international ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

Recent Study Testing International Formulation Shows Significant Increase in GLP-1 HormoneSALT LAKE CITY, Feb. 04, 2025 ...

A small percentage of patients taking GLP-1 medications have experienced vision problems, but a direct causal link with the ...

A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson's disease. The 96-week trial, published in The ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, ...

Explore how GLP-1 agonists, originally for diabetes, could transform addiction treatment by reducing cravings.

About one in eight adults in the United States has tried or currently uses a GLP-1 medication, and a quarter of those users cite weight loss as their main goal. But weight loss doesn't discriminate ...

Divi’s Laboratories share price gained more than 5% in the morning trades on Tuesday, a day after Q3 Results: Do you own it ?

About one in eight adults in the United States has tried or currently uses a GLP-1 medication, and a quarter of those users cite weight loss as their main goal.